Wednesday, March 29, 2023
  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Disclaimer
  • Term & Condition
SEO Tools
Get leads. Get sales. Get growing.
  • Home
  • Free SEO Tools
  • Search Engine Optimization
  • Digital Marketing
  • Marketing Strategy
  • Affiliate Marketing
  • SEO Tools
No Result
View All Result
SEO Tools
  • Home
  • Free SEO Tools
  • Search Engine Optimization
  • Digital Marketing
  • Marketing Strategy
  • Affiliate Marketing
  • SEO Tools
No Result
View All Result
SEO Tools
No Result
View All Result
Home Marketing Strategy

Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)

Admin by Admin
September 30, 2022
in Marketing Strategy
0
Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)
585
SHARES
3.2k
VIEWS
Share on FacebookShare on Twitter

[ad_1]

– ACT for ALS Funding is for an Expanded Access Program to Study SLS-005 in Amyotrophic Lateral Sclerosis Patients Who Do Not Qualify for Clinical Trials

NEW YORK, Sept. 30, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS.

You might also like

Lift in Awareness Correlated with Lift in Consideration,Upwave

Clinical Nutrition Market 2022 By Size & Share, On-Going

Donna Gryn Upped To EVP/Global Marketing Strategy At Republic Records

“Being chosen to again collaborate with the Healey team on an EAP is a privilege and further supports our commitment to provide a meaningful contribution to the ALS community by continuing to explore investigational treatment options in this devastating disorder,” said Raj Mehra Ph.D., Chairman and CEO of Seelos. “Through this EAP, we will be able to offer SLS-005 to people who are unable to meet the entry criteria for any clinical trials. Our hope, through this effort, is to collect additional data to help us advance this therapy through the clinic.”

Under this EAP, Seelos plans to initially enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS in parallel to its ongoing Phase II/III study on the HEALEY Platform.

If you are a person with ALS (PALS) or caregiver of someone with ALS (CALS) and would like more information, please visit: https://seelostherapeutics.com/patients-and-caregivers/

About the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)

The ACT for ALS, Public Law 117-79, among other things, requires the Department of Health and Human Services (HHS), through the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), to implement a Public-Private Partnership for Rare Neurodegenerative Diseases through cooperative agreements or contracts to advance the understanding of neurodegenerative diseases and foster development of treatments for ALS and other rare neurodegenerative diseases. It requires the FDA to publish and implement a 5-year action plan to foster drug development and facilitate access to investigational drugs for ALS and other rare neurodegenerative diseases. Finally, it requires that the FDA award grants or contracts to public and private entities to cover costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children.

More information on ACT for ALS is available here.

More information about NINDS is available here.

About SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion)

SLS-005 is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier and is thought to stabilize proteins and activate autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material. In animal models of several diseases associated with abnormal cellular protein aggregation or storage of pathologic material, SLS-005 has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. SLS-005 is an investigational treatment and is not currently approved by any health authority for medicinal use.

About Amyotrophic Lateral Sclerosis (ALS)

According to the National Institute of Neurological Disorders and Stroke, amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (called atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The disease is progressive, meaning the symptoms get worse over time. The majority of ALS cases (90 percent or more) are considered sporadic. This means the disease seems to occur at random with no clearly associated risk factors and no family history of the disease. Although family members of people with sporadic ALS are at an increased risk for the disease, the overall risk is very low, and most will not develop ALS.

Most people with ALS eventually die from respiratory failure, usually within 3 to 5 years from when the symptoms first appear. However, about 10 percent of people with ALS survive for 10 or more years. Currently, there is no cure for ALS and no effective treatment to halt or reverse, the progression of the disease.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the number of patients to be enrolled in the EAP, the expected duration of the EAP, as well as statements regarding Seelos’ registrational study in the HEALEY platform trial and statements regarding SLS-005’s prospects and potential insights from the EAP. These statements are based on Seelos’ current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos’ business and plans described herein include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies, and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials, the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of Seelos’ business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos’ current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos’ periodic filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2nd Floor
New York, NY 10022
(646) 293-2136
[email protected]
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
[email protected]

SOURCE Seelos Therapeutics, Inc.



[ad_2]

Source_ link

Previous Post

Skimlinks, a Taboola Company, Announces Winners

Next Post

Best SEO Practices For Automotive Business

Admin

Admin

Blogger & Youtuber

Related Posts

Lift in Awareness Correlated with Lift in Consideration,Upwave
Marketing Strategy

Lift in Awareness Correlated with Lift in Consideration,Upwave

by Admin
November 21, 2022
Clinical Nutrition Market 2022 By Size & Share, On-Going
Marketing Strategy

Clinical Nutrition Market 2022 By Size & Share, On-Going

by Admin
October 28, 2022
Donna Gryn Upped To EVP/Global Marketing Strategy At Republic Records
Marketing Strategy

Donna Gryn Upped To EVP/Global Marketing Strategy At Republic Records

by Admin
October 4, 2022
Needle-Free Blood Drawing Devices Market is set to experience a significant growth rate at 4.96% from 2022 to 2029
Marketing Strategy

Needle-Free Blood Drawing Devices Market is set to experience a significant growth rate at 4.96% from 2022 to 2029

by Admin
October 3, 2022
Marketing Strategy

Tory MPs dismiss critical RSPB campaign as ‘marketing strategy’ | Environment

by Admin
October 2, 2022
Next Post
Best SEO Practices For Automotive Business

Best SEO Practices For Automotive Business

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

CLICTA DIGITAL AGENCY LAUNCHES SEO AFFILIATE PROGRAM

CLICTA DIGITAL AGENCY LAUNCHES SEO AFFILIATE PROGRAM

August 25, 2022
N.C. A&T Homecoming Alumni Concert to Feature Jeffrey Osborne and Loose Ends, Oct. 28

N.C. A&T Homecoming Alumni Concert to Feature Jeffrey Osborne and Loose Ends, Oct. 28

August 20, 2022
► Lets Getting Rich blog

► Free SEO & Digital Marketing Tools

► SEO Tools blog

► Latest RVH News

► Find a domain and launch your site today!

Categories

  • Affiliate Marketing
  • Digital Marketing
  • E-Commerce Marketing
  • Email Marketing
  • Marketing Strategy
  • Search Engine Optimization
  • SEO Tools

Don't miss it

From Rags To Riches During The Pandemic, Teamology PR Inspires Startups To Thrive
Digital Marketing

From Rags To Riches During The Pandemic, Teamology PR Inspires Startups To Thrive

December 4, 2022
Here’s how to stop the cost of Christmas from burning a big hole in your wallet
Affiliate Marketing

Here’s how to stop the cost of Christmas from burning a big hole in your wallet

December 3, 2022
Best Digital Marketing Courses: A Review of 5 Top Online Courses
SEO Tools

Best Digital Marketing Courses: A Review of 5 Top Online Courses

December 3, 2022
10 Stars that fans want to see on “The Manager”
Search Engine Optimization

10 Stars that fans want to see on “The Manager”

December 3, 2022
Irish privacy regulator fines Facebook 265 million euros, Marketing & Advertising News, ET BrandEquity
Digital Marketing

Irish privacy regulator fines Facebook 265 million euros, Marketing & Advertising News, ET BrandEquity

November 29, 2022
7 Ways Ecommerce Businesses Use Alternative Data in 2022
SEO Tools

7 Ways Ecommerce Businesses Use Alternative Data in 2022

November 28, 2022
  • About Us
  • Contact Us
  • Disclaimer
  • Home
  • Latest Post
  • Privacy Policy
  • Term & Condition
SEO & Digital Marketing Tools

© 2022 Blog.TopSEOsuperTools.com All Rights Reserved.

No Result
View All Result
  • Landing Page
  • Shop
  • Contact
  • Buy JNews

© 2022 Blog.TopSEOsuperTools.com All Rights Reserved.

What are cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT